Market closed
AstraZeneca/£AZN
08:00
10:10
12:15
14:25
16:30
1D1W1MYTD1Y5YMAX
About AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Ticker
£AZN
Sector
Trading on
LSE
Industry
Pharmaceuticals
Headquarters
Employees
89,900
Website
AstraZeneca Metrics
BasicAdvanced
£155B
Market cap
31.15
P/E ratio
£3.21
EPS
0.15
Beta
£2.34
Dividend rate
2.34%
Dividend yield
Price and volume
Market cap
£155B
Beta
0.15
52-week high
£132.18
52-week low
£94.61
Average daily volume
2.3M
Dividend rate
£2.34
Financial strength
Current ratio
0.889
Quick ratio
0.69
Long term debt to equity
71.304
Total debt to equity
84.966
Dividend payout ratio (TTM)
69.29%
Interest coverage (TTM)
9.65%
Management effectiveness
Return on assets (TTM)
7.68%
Return on equity (TTM)
16.74%
Valuation
Price to earnings (TTM)
31.153
Price to revenue (TTM)
4.046
Price to book
3.92
Price to tangible book (TTM)
-7.38
Price to free cash flow (TTM)
28.218
Dividend yield (TTM)
2.34%
Growth
Revenue change (TTM)
10.45%
Earnings per share change (TTM)
4.27%
3-year revenue growth (CAGR)
18.50%
3-year earnings per share growth (CAGR)
12.79%
3-year dividend per share growth (CAGR)
1.98%
What the Analysts think about AstraZeneca
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for AstraZeneca stock.
AstraZeneca Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
AstraZeneca Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
AstraZeneca News
AllArticlesVideos
Levi & Korsinsky Announces an Investigation on Behalf of AstraZeneca PLC (AZN) Shareholders Who May Have Been Affected by Fraud
Accesswire·10 hours ago
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript
Seeking Alpha·11 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
Accesswire·11 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe
FAQs
What’s the current market cap for AstraZeneca stock?
AstraZeneca (AZN) has a market cap of £155B as of November 13, 2024.
What is the P/E ratio for AstraZeneca stock?
The price to earnings (P/E) ratio for AstraZeneca (AZN) stock is 31.15 as of November 13, 2024.
Does AstraZeneca stock pay dividends?
Yes, the AstraZeneca (AZN) stock pays dividends to shareholders. As of November 13, 2024, the dividend rate is £2.336 and the yield is 2.34%. AstraZeneca has a payout ratio of 69.29% on a trailing twelve-month basis.
When is the next AstraZeneca dividend payment date?
The next AstraZeneca (AZN) dividend payment date is unconfirmed.
What is the beta indicator for AstraZeneca?
AstraZeneca (AZN) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.